Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Theratechnologies Inc
Bullboard Posts
User Avatar Image
(41)
•••
Comment by Spartrapon Jul 10, 2020 1:33pm
168 Views
Post# 31252549

RE:RE:RE:RE:RE:RE:RE:Tesamorelin used by "age-management community"?

RE:RE:RE:RE:RE:RE:RE:Tesamorelin used by "age-management community"?

Thank you for those clarifications, that's reassuring!

SPCEO1 wrote: The composition of matter patent is now set to expire in May 2023, if i recall correctly. They got another extension. Also, THTX tells me the FDA has been made aware of Tailor Made's Tesamorelin claims repeatedly over many years. I imagine it is not viewed by the company of a big enough nuisance to actually file a lawsuit against them, suggesting Tailor Made may have  found it difficult to find a sizable market for their offering too. THTX does not believe the vials Tailor Made produces actually contain Egrifta. 
 

Spartrap wrote:

.. or maybe they can't do anything about it because composition of matter patent just expired in May. Oh well ;-/

https://www.globenewswire.com/news-release/2014/06/09/1473884/0/en/Theratechnologies-Obtains-U-S-Patent-Term-Extension-for-Tesamorelin.html

 

Spartrap wrote:

 

TH should consider taking legal action against those Tailor Made Compounding guys, if their patent is still of any value.


 




Bullboard Posts
Dealroom for high-potential pre-IPO opportunities